A phosphorylation-wide sncRNA screen reveals Protein Functional Effector sncRNAs (pfeRNAs) in human lung somatic cells.

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Cancer Letters

• Publication date

  2017-06-28

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/j.canlet.2017.03.017PMID 28323037
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Non-small Cell Lung Cancer: Current Therapies and New Targeted Treatments

  2021cited by this paper
• The regulation of oncogenic Ras/ERK signalling by dual-specificity mitogen activated protein kinase phosphatases (MKPs)

  2016cited by this paper
• New and emerging targeted treatments in advanced non-small-cell lung cancer.

  2016cited by this paper
• Cancer statistics, 2016

  2016cited by this paper
• Mitogen-activated protein kinases as key players in osmotic stress signaling.

  2016cited by this paper
• Molecular Pathways: Targeting the Cyclin D–CDK4/6 Axis for Cancer Treatment

  2015cited by this paper
• Targeting the translation machinery in cancer

  2015cited by this paper
• Differential Effects of Tyrosine Kinase Inhibitors on Normal and Oncogenic EGFR Signaling and Downstream Effectors

  2015cited by this paper
• Human anti-nucleolin recombinant immunoagent for cancer therapy

  2015cited by this paper
• A piRNA-like small RNA interacts with and modulates p-ERM proteins in human somatic cells

  2015cited by this paper
• Ebp1 activates podoplanin expression and contributes to oral tumorigenesis

  2014cited by this paper
• The noncoding RNA revolution-trashing old rules to forge new ones.

  2014cited by this paper
• Wnt signaling pathway in non-small cell lung cancer.

  2014cited by this paper
• Regulation of microRNA biogenesis

  2014cited by this paper
• Ultradeep human phosphoproteome reveals a distinct regulatory nature of Tyr and Ser/Thr-based signaling.

  2014cited by this paper
• Ultrasensitivity part II: multisite phosphorylation, stoichiometric inhibitors, and positive feedback.

  2014cited by this paper
• Epidemiology: The dominant malignancy

  2014cited by this paper
• What a tangled web we weave: emerging resistance mechanisms to inhibition of the phosphoinositide 3-kinase pathway.

  2013cited by this paper
• Novel dimensions of piRNAs in cancer.

  2013cited by this paper
• New approaches to targeted therapy in lung cancer.

  2012cited by this paper
• Global cancer transitions according to the Human Development Index (2008-2030): a population-based study.

  2012cited by this paper
• Differential sensitivities to tyrosine kinase inhibitors in NSCLC harboring EGFR mutation and ALK translocation.

  2012cited by this paper
• Differential Protein Stability and ALK Inhibitor Sensitivity of EML4-ALK Fusion Variants

  2012cited by this paper
• Are snoRNAs and snoRNA host genes new players in cancer?

  2012cited by this paper
• RNA-binding protein nucleolin in disease

  2012cited by this paper
• Cytoskeletal dynamics and lung fluid balance.

  2012cited by this paper
• Potential mechanism of interleukin‐8 production from lung cancer cells: An involvement of EGF–EGFR–PI3K–Akt–Erk pathway

  2012cited by this paper
• Integrating diverse genomic data using gene sets

  2011cited by this paper
• System-Wide Temporal Characterization of the Proteome and Phosphoproteome of Human Embryonic Stem Cell Differentiation

  2011cited by this paper
• Small nucleolar RNA 42 acts as an oncogene in lung tumorigenesis

  2011cited by this paper
• miRDeep2 accurately identifies known and hundreds of novel microRNA genes in seven animal clades

  2011cited by this paper
• Epidermal growth factor receptor in relation to tumor development: EGFR gene and cancer

  2010cited by this paper
• Differential expression analysis for sequence count data

  2010cited by this paper
• Population-based differences in treatment outcome following anticancer drug therapies.

  2010cited by this paper
• Quantitative Phosphoproteomics Reveals Widespread Full Phosphorylation Site Occupancy During Mitosis

  2010cited by this paper
• Non-small-cell lung cancer harbouring mutations in the EGFR kinase domain

  2010cited by this paper
• Ultrafast and memory-efficient alignment of short DNA sequences to the human genome

  2009cited by this paper
• Searching for SNPs with cloud computing

  2009cited by this paper
• Clinical outcomes in non-small-cell lung cancer patients with EGFR mutations: pooled analysis

  2009cited by this paper
• Multisite protein phosphorylation – from molecular mechanisms to kinetic models

  2009cited by this paper
• Targeting RAS and PI3K in lung cancer

  2008cited by this paper
• Lung cancer.

  2008cited by this paper
• Nucleolin: a multiFACeTed protein.

  2007cited by this paper
• Mechanisms of specificity in protein phosphorylation

  2007cited by this paper
• Mechanisms of specificity in protein phosphorylation

  2007cited by this paper
• Regulation of p53 translation and induction after DNA damage by ribosomal protein L26 and nucleolin.

  2005cited by this paper
• EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy

  2004cited by this paper
• Rational siRNA design for RNA interference

  2004cited by this paper
• The JNK-interacting Protein-1 Scaffold Protein Targets MAPK Phosphatase-7 to Dephosphorylate JNK*

  2003cited by this paper
• The origins of protein phosphorylation

  2002cited by this paper
• Epidermal growth factor receptor family in lung cancer and premalignancy.

  2002cited by this paper
• Multisite phosphorylation of a CDK inhibitor sets a threshold for the onset of DNA replication

  2001cited by this paper
• Structural and Evolutionary Relationships among Protein Tyrosine Phosphatase Domains

  2001cited by this paper
• Kinetic and catalytic mechanisms of protein kinases.

  2001cited by this paper
• Molecular dissection of nucleolin's role in growth and cell proliferation: new insights

  1999cited by this paper
• Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans

  1998cited by this paper

• PD-L1 pfeRNAs as blood-based predictors of treatment response of unresectable malignant pleural mesothelioma patients administered Durvalumab with cisplatin and pemetrexed as first-line therapy

  2025influential citation
• Protein Functional Effector (pfe) Noncoding RNAS Are Identical to Fragments from Various Noncoding RNAs

  2025cites this paper
• TERT PfeRNA regulates telomere length during cellular senescence of normal human bronchial epithelial cells

  2025cites this paper
• pfeRNAs- A Novel Class of Small Non-Coding RNAs With Real Translational Potential.

  2023cites this paper
• A TRIzol-based method for high recovery of plasma sncRNAs approximately 30 to 60 nucleotides

  2022cites this paper
• A Cost-Effective and Non-Invasive pfeRNA-Based Test Differentiates Benign and Suspicious Pulmonary Nodules from Malignant Ones

  2021cites this paper
• PIWI-interacting RNAs in human cancer.

  2020cites this paper
• Protein functional effector sncRNAs (pfeRNAs) in lung cancer.

  2017cites this paper